Viatris agreed to acquire Pacira BioSciences for about $1.65 billion, adding commercial-stage non-opioid pain assets to its portfolio. The deal is structured as a cash transaction and comes as branded and generics operators continue to reposition around chronic pain and non-opioid mechanistic differentiation. Pacira’s product pipeline and commercialization scale are expected to help Viatris extend revenue and strengthen exposure to pain indications outside the opioid class. The acquisition also signals persistent M&A interest in late-stage assets where payoff timing aligns with patent cliffs and payer dynamics. For the biotech and pharma ecosystem, the transaction highlights how “portfolio math” still drives deal flow: companies are buying in-market franchises rather than waiting years for early-stage programs to mature, especially where differentiated pain mechanisms may support both differentiation and lifecycle extension.